Adverse Event Reporting Rule: FDA Seeks Comments On SNOMED Vs. MedDRA
Executive Summary
FDA seeks comments on the use of SNOMED versus MedDRA terminology for suspected adverse event reporting
You may also be interested in...
Adverse Event Reports Should Be 80% Electronic By Year End, FDA Hopes
FDA hopes to receive 80% of adverse event reports in electronic format by the end of the year, CDER Division of Drug Risk Evaluation Associate Director Min Chen said
Adverse Event Reports Should Be 80% Electronic By Year End, FDA Hopes
FDA hopes to receive 80% of adverse event reports in electronic format by the end of the year, CDER Division of Drug Risk Evaluation Associate Director Min Chen said
FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says